New Drugs Hailed as a 'Pivotal Moment' in Addressing Drug-Resistant Gonorrhoea
The first new treatments for gonorrhoea in decades are being viewed as a "significant breakthrough" in the battle against increasingly resistant strains of the infection, according to researchers.
An International Challenge
Cases of gonorrhoea are on the rise globally, with data suggesting more than 82 million infections annually. Notably increased rates are reported in Africa and countries within the WHO's Western Pacific region, which encompasses China and Mongolia to New Zealand. In England, cases have reached a historical peak, while rates across Europe in 2023 were significantly elevated compared to figures for 2014.
“The clearance of novel therapies for gonorrhoea is an significant and necessary advancement in the context of increasing worldwide cases, increasing antimicrobial resistance and the highly restricted therapeutic options currently available.”
Health officials are increasingly worried about the increase in treatment-resistant strains. The World Health Organization has classified it as a "priority pathogen". A tracking program showed that the effectiveness of standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.
A Pair of Novel Drugs Gain Approval
One new antibiotic, marketed under the name Nuzolvence, was cleared by the US FDA in recent days for treating gonorrhoea. This infection can lead to serious health problems, including the inability to conceive. Researchers hope that focused deployment of this new drug will help delay the emergence of superbugs.
Another new antibiotic, developed by the drugmaker GlaxoSmithKline, also received approval in close succession. This medication, which is employed against UTIs, was shown in trials to be successful in treating drug-resistant strains of the gonorrhoea bacteria.
A Novel Approach to Creation
Zoliflodacin stemmed from a new, not-for-profit approach for drug creation. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the drug firm its industry partner to see it through.
“This authorization marks a significant shift in the treatment of superbug gonorrhoea, which up to this point has been evolving faster than our drug pipeline.”
Research Study Results and Global Access
Based on findings detailed in a prominent scientific publication, zoliflodacin successfully treated the vast majority of uncomplicated infections. This puts it on an comparable level with the typical regimen, which combines a dual-drug approach. The study included over 900 patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.
As part of the agreement of its unique model, the non-profit has the rights to make available and distribute the drug in a wide range of low-income and middle-income countries.
Clinicians directly involved have voiced hope. Access to a easy-to-administer therapy of this kind is hailed as a "revolutionary step" for gonorrhoea control. This is considered essential to alleviate the strain of the infection for people and to halt the transmission of extremely resistant gonorrhoea worldwide.
